{"filing": {"accession": "0001493152-26-019409", "cik": "0001828673", "ticker": "HCWB", "company_name": "HCW Biologics Inc.", "form_type": "DEF 14A", "filing_type": "DEF 14A", "filing_date": "2026-04-28", "accepted_datetime": null, "acceptance_datetime": null, "accepted_at": null, "primary_doc_url": "https://www.sec.gov/Archives/edgar/data/1828673/000149315226019409/0001493152-26-019409-index.htm", "filing_url": "https://www.sec.gov/Archives/edgar/data/1828673/000149315226019409/0001493152-26-019409-index.htm", "period_of_report": "2026-04-28"}, "html_url": "/api/filings/000149315226019409/stream", "exhibits": [], "sections": [], "tables": [{"table_index": 11, "table_type": "text", "caption": null, "header_text": "Sincerely,"}, {"table_index": 13, "table_type": "text", "caption": null, "header_text": "Time and Date:June 15, 2026 at 10:00 a.m., Eastern Time."}, {"table_index": 15, "table_type": "text", "caption": null, "header_text": "5. To approve, for purposes of complying with Nasdaq Listing\n Rule 5635(d), the repricing of certain warrants issued on November 20, 2025 to purchase up to 3,020,410 shares of our Common Stock\n (the \u201c"}, {"table_index": 16, "table_type": "text", "caption": null, "header_text": "By\nOrder of the Board of Directors,"}, {"table_index": 18, "table_type": "text", "caption": null, "header_text": "Page"}, {"table_index": 22, "table_type": "text", "caption": null, "header_text": "Q:What\n is included in the proxy materials?"}, {"table_index": 35, "table_type": "text", "caption": null, "header_text": "4.To approve, for purposes\n of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of our Common Stock upon exercise of up to 2,477,292 Common Stock\n Purchase Warrants (the \u201cCommon Warr"}, {"table_index": 136, "table_type": "text", "caption": null, "header_text": "NameAgePositionDirector Since"}, {"table_index": 137, "table_type": "text", "caption": null, "header_text": "(1)Member\n of our audit committee"}, {"table_index": 140, "table_type": "text", "caption": null, "header_text": "NameAgePositionDirector\n Since"}, {"table_index": 141, "table_type": "text", "caption": null, "header_text": "(1)Member\n of our audit committee"}, {"table_index": 144, "table_type": "text", "caption": null, "header_text": "NameFees Earned or Paid in Cash ($)Awards\n ($)(1)(3)Total ($)"}, {"table_index": 145, "table_type": "financial", "caption": null, "header_text": "(1)The\n amounts reported in this column represent the aggregate grant date fair value for financial\n statement reporting purposes of stock options granted 2024 and 2025 as determined in accordance\n wi"}, {"table_index": 146, "table_type": "text", "caption": null, "header_text": "NameShares Subject to Outstanding Stock Options(1)"}, {"table_index": 147, "table_type": "text", "caption": null, "header_text": "(1)Our\n non-employee directors held these outstanding stock options as of December 31, 2025."}, {"table_index": 152, "table_type": "text", "caption": null, "header_text": "Year Ended December 31,"}, {"table_index": 167, "table_type": "text", "caption": null, "header_text": "\u25cfStock\n Price Requirements: Many brokerage firms have internal policies and practices that have the effect of discouraging individual\n brokers from recommending lower-priced securities to their client"}, {"table_index": 168, "table_type": "text", "caption": null, "header_text": "\u25cfwhether\n the Panel grants us additional time to regain compliance with the Minimum Bid Price Rule;"}, {"table_index": 173, "table_type": "text", "caption": null, "header_text": "\u25cfeach five to twenty shares\n of Common Stock owned by a stockholder (depending on the Reverse Stock Split ratio selected by the Board), will be combined\n into one new share of Common Stock;"}, {"table_index": 174, "table_type": "text", "caption": null, "header_text": "Reverse Stock Split RatioNumber of Sharesof Common Stock AuthorizedNumber ofShares ofCommon StockOutstanding(1)Number\n of Sharesof Common StockReserved forFuture Issuance(2)Number of Sharesof Common S"}, {"table_index": 200, "table_type": "text", "caption": null, "header_text": "Name of Beneficial OwnerCommon StockOptions Exercisable within 60 daysAggregate Number of Shares Beneficially OwnedPercentage of Shares Beneficially Owned"}, {"table_index": 202, "table_type": "text", "caption": null, "header_text": "(1)Consists\n of (a) 398,719 shares held directly by Dr. Hing C. Wong and (b) 103,192 shares held by Dr.\n Hing C. Wong and Ms. Bee Yau Huang."}, {"table_index": 205, "table_type": "text", "caption": null, "header_text": "NameAgePosition"}, {"table_index": 208, "table_type": "text", "caption": null, "header_text": "Name and Principal PositionFiscal YearSalary($)Bonus($)Non-Equity Incentive Plan Compensation ($)(2)All Other Compensation($)(1)Total($)"}, {"table_index": 219, "table_type": "text", "caption": null, "header_text": "NameGrant Date(#) Exercisable(#) Unexercisable(#) Option Exercise Price ($)(2)Option Expiration Date"}, {"table_index": 220, "table_type": "text", "caption": null, "header_text": "(1)All of the outstanding equity awards were granted under our 2021 Plan and are subject to acceleration of vesting as described in above."}, {"table_index": 223, "table_type": "text", "caption": null, "header_text": "(a)(b)(c)"}, {"table_index": 224, "table_type": "text", "caption": null, "header_text": "(1)Includes\n the 2019 Plan and the 2021 Plan."}], "exhibits_pending": true, "cdn_html": true, "response_time_ms": 103}